Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
My north star: We disclose—fast, fully, and on our terms. The “wait for more data” option is a mirage. It exposes the company to criminal liability under FDA adverse-event reporting rules, potential DOJ investigation, securities fraud charges, and derivative litigation that could destroy the firm.Read the full answer
As CEO, I would not wait six months and I would not let the board delay disclosure while patients remain exposed to an unreported serious risk. I would treat this as a patient-safety, regulatory, legal, and trust crisis—not merely a financial-risk issue. My guiding decisions would be: Patient safety comes first.Read the full answer